Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
Pioglitazone418 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A18671 | 27003143 | Dig Dis Sci | Novel Pharmacotherapy Options for NASH. | 2016 | Details |
| A18741 | 26976710 | Endocrinol Nutr | Effect of incretin therapies compared to pioglitazone and gliclazide in non-alcoholic fatty liver disease in diabetic patients not controlled on metformin alone: An observational, pilot study. | 2016 | Details |
| A18785 | 26942734 | Dig Dis Sci | Medical and Surgical Treatment Options for Nonalcoholic Steatohepatitis. | 2016 | Details |
| A19001 | 26825546 | Eur J Pharmacol | Effects of combined PPAR-γ and PPAR-α agonist therapy on fructose induced NASH in rats: Modulation of gene expression. | 2016 | Details |
| A19055 | 26797396 | Am J Physiol Gastrointest Liver Physiol | Pioglitazone attenuates hepatic inflammation and fibrosis in phosphatidylethanolamine N-methyltransferase-deficient mice. | 2016 | Details |
| A19099 | 26770262 | Therap Adv Gastroenterol | Practice patterns in NAFLD and NASH: real life differs from published guidelines. | 2016 | Details |
| A19112 | 26756202 | Diabet Med | Familial partial lipodystrophy linked to a novel peroxisome proliferator activator receptor -γ (PPARG) mutation, H449L: a comparison of people with this mutation and those with classic codon 482 Lamin A/C (LMNA) mutations. | 2016 | Details |
| A19186 | 28670148 | Clin Med Insights Ther | Nonalcoholic Fatty Liver Disease: Epidemiology, Pathogenesis, Natural History, Diagnosis, and Current Treatment Options. | 2016 | Details |
| A19296 | 26641143 | Expert Rev Gastroenterol Hepatol | The role of insulin resistance in nonalcoholic steatohepatitis and liver disease development--a potential therapeutic target? | 2015 | Details |
| A19457 | 26557974 | Iran J Basic Med Sci | Effect of pioglitazone, quercetin and hydroxy citric acid on extracellular matrix components in experimentally induced non-alcoholic steatohepatitis. | 2015 | Details |
| A19745 | 26378648 | Semin Liver Dis | Pharmacotherapy for Nonalcoholic Fatty Liver Disease. | 2015 | Details |
| A19787 | 26349165 | Trop Gastroenterol | Nonalcoholic Fatty Liver Disease--The Clinician's Perspective. | 2015 | Details |
| A19891 | 26281317 | Turk J Med Sci | Effect of pioglitazone, quercetin, and hydroxy citric acid on vascular endothelial growth factor messenger RNA (VEGF mRNA) expression in experimentally induced nonalcoholic steatohepatitis (NASH). | 2015 | Details |
| A19942 | 26252777 | PLoS One | Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease. | 2015 | Details |
| A19984 | 26226097 | Clin Gastroenterol Hepatol | Nonalcoholic Fatty Liver Disease Review: Diagnosis, Treatment, and Outcomes. | 2015 | Details |
| A20055 | 26189925 | Hepatology | Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: A systematic review and network meta-analysis. | 2015 | Details |
| A20262 | 26057287 | JAMA | Nonalcoholic fatty liver disease: a systematic review. | 2015 | Details |
| A20309 | 26035752 | Int J Mol Sci | Effect of Chronic Pioglitazone Treatment on Hepatic Gene Expression Profile in Obese C57BL/6J Mice. | 2015 | Details |
| A20576 | 25875942 | PLoS One | LPSF/GQ-02 inhibits the development of hepatic steatosis and inflammation in a mouse model of non-alcoholic fatty liver disease (NAFLD). | 2015 | Details |
| A20584 | 25873078 | Exp Biol Med (Maywood) | Nonalcoholic fatty liver disease: update on pathogenesis, diagnosis, treatment and the role of S-adenosylmethionine. | 2015 | Details |
| A20726 | 25774446 | Curr Opin Gastroenterol | Nonalcoholic fatty liver disease: new treatments. | 2015 | Details |
| A20827 | 25708949 | Naunyn Schmiedebergs Arch Pharmacol | Protective effect of boswellic acids versus pioglitazone in a rat model of diet-induced non-alcoholic fatty liver disease: influence on insulin resistance and energy expenditure. | 2015 | Details |
| A20839 | 25701721 | Eur J Pharmacol | Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats. | 2015 | Details |
| A20908 | 25649191 | Obes Res Clin Pract | Elevation of branched-chain amino acid levels in diabetes and NAFL and changes with antidiabetic drug treatment. | 2015 | Details |
| A21089 | 25542756 | Eur J Pharmacol | Ameliorative effect of nicorandil on high fat diet induced non-alcoholic fatty liver disease in rats. | 2014 | Details |
| A21230 | 25468829 | Int J Obes (Lond) | Fetuin-A: a novel link between obesity and related complications. | 2014 | Details |
| A21291 | 25429853 | Aliment Pharmacol Ther | NASH resolution is associated with improvements in HDL and triglyceride levels but not improvement in LDL or non-HDL-C levels. | 2014 | Details |
| A21310 | 25414939 | Postgrad Med | Diabetes mellitus as a novel risk factor for gastrointestinal malignancies. | 2014 | Details |
| A21413 | 25339808 | World J Gastroenterol | Non-alcoholic fatty liver disease: what has changed in the treatment since the beginning? | 2014 | Details |
| A21440 | 25317811 | Eur Rev Med Pharmacol Sci | Pioglitazone, quercetin and hydroxy citric acid effect on cytochrome P450 2E1 (CYP2E1) enzyme levels in experimentally induced non alcoholic steatohepatitis (NASH). | 2014 | Details |
| A21558 | 25232252 | World J Gastroenterol | Management of nonalcoholic fatty liver disease: an evidence-based clinical practice review. | 2014 | Details |
| A21600 | 25195022 | J Chromatogr B Analyt Technol Biomed Life Sci | A validated liquid chromatography tandem mass spectrometry method for simultaneous determination of pioglitazone, hydroxypioglitazone, and ketopioglitazone in human plasma and its application to a clinical study. | 2014 | Details |
| A21642 | 25160038 | J Transl Med | Extracts from Salvia-Nelumbinis naturalis alleviate hepatosteatosis via improving hepatic insulin sensitivity. | 2014 | Details |
| A21705 | 25105443 | Ann Transplant | Thiazolidinedione therapy versus lifestyle recommendation in the treatment of post-liver transplant graft steatosis. | 2014 | Details |
| A21823 | 25024593 | World J Gastroenterol | Modern approach to the clinical management of non-alcoholic fatty liver disease. | 2014 | Details |
| A21855 | 24997826 | Zhongguo Yi Xue Ke Xue Yuan Xue Bao | Effect of piglitazone and metformin on retinol-binding protein-4 and adiponectin in patients with type 2 diabetes mellitus complicated with non-alcohol fatty acid liver diseases. | 2014 | Details |
| A21982 | 24916329 | J Magn Reson Imaging | Phagocytic function of Kupffer cells in mouse nonalcoholic fatty liver disease models: Evaluation with superparamagnetic iron oxide. | 2014 | Details |
| A22176 | 24766298 | Expert Opin Drug Discov | Evolving therapies for non-alcoholic steatohepatitis. | 2014 | Details |
| A22184 | 24761121 | Pharmacognosy Res | Pioglitazone, quercetin and hydroxy citric acid effect on hepatic biomarkers in Non Alcoholic Steatohepatitis. | 2014 | Details |
| A22253 | 24717764 | Curr Opin Gastroenterol | State of the art: treatment of nonalcoholic steatohepatitis. | 2014 | Details |
| A22393 | 24622831 | J Physiol Pharmacol | Comparative effect of pioglitazone, quercetin and hydroxy citric acid on the status of lipid peroxidation and antioxidants in experimental non-alcoholic steatohepatitis. | 2014 | Details |
| A22429 | 24587650 | World J Gastroenterol | Clinical approaches to non-alcoholic fatty liver disease. | 2014 | Details |
| A22454 | 24558317 | ScientificWorldJournal | Pioglitazone upregulates angiotensin converting enzyme 2 expression in insulin-sensitive tissues in rats with high-fat diet-induced nonalcoholic steatohepatitis. | 2014 | Details |
| A22819 | 24287794 | Endocrine | Non-alcoholic fatty liver disease: a diabetologist's perspective. | 2013 | Details |
| A22854 | 24251709 | J Gastroenterol Hepatol | Treatment of non-alcoholic fatty liver disease. | 2013 | Details |
| A22871 | 24264040 | Int J Mol Sci | Nonalcoholic Fatty liver: a possible new target for type 2 diabetes prevention and treatment. | 2013 | Details |
| A22879 | 24259612 | Ann Pharmacother | Resistant nonalcoholic fatty liver disease amelioration with rosuvastatin and pioglitazone combination therapy in a patient with metabolic syndrome. | 2013 | Details |
| A22983 | 24134913 | Biochem Pharmacol | Morin reduces hepatic inflammation-associated lipid accumulation in high fructose-fed rats via inhibiting sphingosine kinase 1/sphingosine 1-phosphate signaling pathway. | 2013 | Details |
| A23019 | 24114819 | Ann Hepatol | Pioglitazone upregulates hepatic angiotensin converting enzyme 2 expression in rats with steatohepatitis. | 2014 | Details |
| A23242 | 23930133 | Hepat Mon | The effect of pioglitazone and metformin on liver function tests, insulin resistance, and liver fat content in nonalcoholic Fatty liver disease: a randomized double blinded clinical trial. | 2013 | Details |
| A23515 | 23718573 | Aliment Pharmacol Ther | Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis. | 2013 | Details |
| A23616 | 23625197 | Curr Diab Rep | The future of thiazolidinedione therapy in the management of type 2 diabetes mellitus. | 2013 | Details |
| A23674 | 23576902 | ScientificWorldJournal | Current concepts and management approaches in nonalcoholic fatty liver disease. | 2013 | Details |
| A23826 | 25755474 | J Clin Exp Hepatol | Successful Treatment of Rapid Onset, Symptomatic de novo Non-alcoholic Steatohepatitis Following Liver Transplantation: A Case Report. | 2013 | Details |
| A23979 | 23329465 | Drugs | Nonalcoholic fatty liver disease: current issues and novel treatment approaches. | 2013 | Details |
| A24135 | 25755455 | J Clin Exp Hepatol | A Randomized Controlled Trial Comparing Efficacy of Pentoxifylline and Pioglitazone on Metabolic Factors and Liver Histology in Patients with Non-alcoholic Steatohepatitis. | 2012 | Details |
| A24174 | 23148186 | Ther Adv Endocrinol Metab | An Endocrine Perspective of Nonalcoholic Fatty Liver Disease (NAFLD). | 2011 | Details |
| A24201 | 23127227 | Clin Exp Pharmacol Physiol | Thiazolidinediones improve hepatic fibrosis in rats with non-alcoholic steatohepatitis by activating the adenosine monophosphate-activated protein kinase signalling pathway. | 2012 | Details |
| A24238 | 23087748 | Hepat Mon | Effects of metformin, pioglitazone, and silymarin treatment on non-alcoholic Fatty liver disease: a randomized controlled pilot study. | 2012 | Details |
| A24250 | 23075940 | Curr Opin Clin Nutr Metab Care | Vitamin E and nonalcoholic fatty liver disease. | 2012 | Details |
| A24297 | 23028489 | PLoS One | Metabolomic profiling to identify predictors of response to vitamin E for non-alcoholic steatohepatitis (NASH). | 2012 | Details |
| A24387 | 22949894 | Case Rep Gastroenterol | Dipeptidyl Peptidase IV Inhibitor Improves Insulin Resistance and Steatosis in a Refractory Nonalcoholic Fatty Liver Disease Patient: A Case Report. | 2012 | Details |
| A24411 | 22927782 | ScientificWorldJournal | The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone. | 2012 | Details |
| A24422 | 22913901 | Postgrad Med | Managing diabetes in patients with chronic liver disease. | 2012 | Details |
| A24599 | 22707355 | Hepatology | Pioglitazone and vitamin E for nonalcoholic steatohepatitis: a cost utility analysis. | 2012 | Details |
| A24655 | 25755424 | J Clin Exp Hepatol | Management of Non-alcoholic Fatty Liver Disease and Steatohepatitis. | 2012 | Details |
| A24757 | 22532269 | Hepatology | Relationship between adipose tissue insulin resistance and liver histology in nonalcoholic steatohepatitis: a pioglitazone versus vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis trial follow-up study. | 2012 | Details |
| A24766 | 22521558 | Clin Res Hepatol Gastroenterol | Non-alcoholic fatty liver disease in children. | 2012 | Details |
| A24779 | 22505328 | Hepatology | Hydrogen-rich water prevents progression of nonalcoholic steatohepatitis and accompanying hepatocarcinogenesis in mice. | 2012 | Details |
| A24836 | 22444524 | Dig Liver Dis | Spirulina improves non-alcoholic steatohepatitis, visceral fat macrophage aggregation, and serum leptin in a mouse model of metabolic syndrome. | 2012 | Details |
| A24928 | 22348670 | Ugeskr Laeger | [Prognosis and treatment of non-alcoholic fatty liver disease and steatohepatitis]. | 2012 | Details |
| A24939 | 22338037 | Am J Clin Nutr | Choline intake in a large cohort of patients with nonalcoholic fatty liver disease. | 2012 | Details |
| A24984 | 22278337 | Diabetologia | Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. | 2012 | Details |
| A25060 | 24713803 | Ann Gastroenterol | Non-alcoholic steatohepatitis: the therapeutic challenge of a global epidemic. | 2012 | Details |
| A25238 | 22059955 | Health Technol Assess | Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review. | 2011 | Details |
| A25246 | 22050199 | Aliment Pharmacol Ther | Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis. | 2011 | Details |
| A25323 | 21956711 | Diabetologia | Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial. | 2011 | Details |
| A25342 | 21946918 | Mol Med Rep | Nifedipine prevents hepatic fibrosis in a non-alcoholic steatohepatitis model induced by an L-methionine-and choline-deficient diet. | 2011 | Details |
| A25381 | 21906525 | Zhong Xi Yi Jie He Xue Bao | [Effects of Chinese herbal medicine Jiangzhi Granule on expressions of liver X receptor α and sterol regulatory element-binding protein-1c in a rat model of non-alcoholic fatty liver disease]. | 2011 | Details |
| A25397 | 21893273 | Gastroenterol Clin North Am | Nonalcoholic fatty liver disease: pharmacologic and surgical options. | 2011 | Details |
| A25420 | 21875310 | Crit Rev Clin Lab Sci | Non-alcoholic fatty liver disease. | 2011 | Details |
| A25440 | 21839075 | Eur J Pharmacol | Berberine reducing insulin resistance by up-regulating IRS-2 mRNA expression in nonalcoholic fatty liver disease (NAFLD) rat liver. | 2011 | Details |
| A25499 | 21765869 | Therap Adv Gastroenterol | The role of insulin-sensitizing agents in the treatment of nonalcoholic steatohepatitis. | 2011 | Details |
| A25502 | 21764223 | Med Hypotheses | Full-spectrum antioxidant therapy featuring astaxanthin coupled with lipoprivic strategies and salsalate for management of non-alcoholic fatty liver disease. | 2011 | Details |
| A25641 | 21612059 | Vnitr Lek | [Steatosis and steatohepatitis in diabetic patient]. | 2011 | Details |
| A25655 | 21577310 | World J Gastrointest Pharmacol Ther | Is there any progress in the treatment of non-alcoholic fatty liver disease? | 2011 | Details |
| A25681 | 21556019 | Nat Rev Endocrinol | Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment. | 2011 | Details |
| A25683 | 21549113 | Eur J Pharmacol | Pentoxifylline and melatonin in combination with pioglitazone ameliorate experimental non-alcoholic fatty liver disease. | 2011 | Details |
| A26370 | 20578268 | Hepatology | A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. | 2010 | Details |
| A26478 | 20415685 | Diabetes Obes Metab | The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease. | 2010 | Details |
| A26709 | 19921118 | Adv Ther | Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: Current status. | 2009 | Details |
| A26791 | 19779336 | Curr Opin Lipidol | Thiazolidinediones and the liver in humans. | 2009 | Details |
| A26842 | 19670918 | Drug Saf | Liver safety in patients with type 2 diabetes treated with pioglitazone: results from a 3-year, randomized, comparator-controlled study in the US. | 2009 | Details |
| A26984 | 19412008 | J Pediatr Gastroenterol Nutr | Pharmacological interventions for nonalcoholic fatty liver disease in adults and in children: a systematic review. | 2009 | Details |
| A27014 | 19353360 | Ann Med | New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD). | 2009 | Details |
| A27163 | 19065650 | Hepatology | Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. | 2009 | Details |
| A27258 | 18822121 | BMC Mol Biol | Pioglitazone retrieves hepatic antioxidant DNA repair in a mice model of high fat diet. | 2008 | Details |
| A27265 | 18804555 | Contemp Clin Trials | Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. | 2008 | Details |
| A27417 | 18422468 | Expert Opin Pharmacother | Pleiotropic effects of thiazolidinediones. | 2008 | Details |
| A27489 | 18296738 | Exp Biol Med (Maywood) | Evidence-based efficacy of Kampo formulas in a model of non alcoholic fatty liver. | 2008 | Details |